Cheng Lu

Title: Innovations of Cheng Lu in Cancer Treatment

Introduction

Cheng Lu is a notable inventor based in Hong Kong, CN. He has made significant contributions to the field of cancer treatment through his innovative research and development of novel compounds. His work focuses on the creation of triptolide derivatives that exhibit promising anti-cancer properties.

Latest Patents

Cheng Lu holds a patent for "Triptolide derivatives and preparation method and use thereof." This patent details the development of triptolide-nucleic acid aptamer derivatives, which are designed to enhance targeting and efficacy in cancer therapy. The invention utilizes a nucleic acid aptamer and triptolide or its modified compounds as starting materials. A linking group is introduced at the C-14 hydroxyl group, epoxy groups, and five-membered ring lactones in triptolide, which is then connected to a nucleic acid aptamer. The resulting triptolide-nucleic acid aptamer derivatives demonstrate good targeting, high anti-cancer activity, low toxicity, and excellent water solubility, making them suitable for production.

Career Highlights

Cheng Lu is affiliated with Hong Kong Baptist University, where he conducts his research and development activities. His work has garnered attention for its scientific rigor and potential applications in the medical field. He has successfully developed a preparation method that is both reasonable and controllable, ensuring high quality and repeatability in production.

Collaborations

Cheng Lu collaborates with esteemed colleagues such as Ge Zhang and Aiping Lu. Their combined expertise contributes to the advancement of research in the field of cancer treatment.

Conclusion

Cheng Lu's innovative work in developing triptolide derivatives represents a significant advancement in cancer therapy. His contributions not only highlight the potential of these compounds but also pave the way for future research and applications in the medical field.